Additionally, MRI biomarkers of the tumor microenvironment, for example, necrosis, hypoxia with/without neovascularization, oxidative phosphorylation, and aerobic glycolysis, are predictive of the treatment response to bevacizumab in patients with glioblastoma.329 Gadolinium ethoxybenzyl diethylenetriamine (Gd-EOB-DTPA; a liver-specific contrast agent)-enhanced MRI is an imaging biomarker of OATP1B3, a transporter of Gd-EOB-DTPA.330 The expression of OATP1B3 is induced by Wnt/β-catenin mutation. Here, SLCO1B3 is linked to glioblastoma.